Kuon, Jonas
Hommertgen, Adriane
Krisam, Johannes
Lasitschka, Felix
Stenzinger, Albrecht
Blasi, Miriam
Bozorgmehr, Farastuk
Maenz, Martin
Kieser, Meinhard
Schneider, Marc
Thomas, Michael
Funding for this research was provided by:
Celgene
AstraZeneca Schweiz
Article History
Received: 25 October 2019
Accepted: 24 March 2020
First Online: 22 April 2020
Ethics approval and consent to participate
: Central ethics approval has been confirmed from the Ethics Committee of the Medical Faculty of the University of Heidelberg 24.10.2017 (AFmu-681/2016) and we will not begin recruiting at other centers in the trial until local ethics approval has been obtained.Written informed consent is obtained from all participants. Additionally, the Paul Ehrlich Institute (competent authority for approval of clinical trials using medicinal products for human use in Germany) approved the study on 03.07.2017.
: Not applicable as no individual patient data are contained in this manuscript.
: The DURATION trial received funding from AstraZeneca and Celgene. AstraZeneca and Celgene have not been involved in the study design and has no role in data collection, management, data analysis and interpretation, or in the decision to submit this protocol for publication.All authors declare that they have no competing conflicts of interest.